ClinicalTrials.gg
CompletedNCT05086354JUMPUpdated Feb 11, 2022

Examining a Training Program for for Acute Lymphoblastic Leukemia Childhood Cancer Survivors

An interventional study of JUMP in Childhood Cancer, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-02-11.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Mar 2018, registered Sep 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Study summary

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with the peak incidences occurring in children two to five years of age. Children with ALL received neurotoxic chemotherapy agents for two to three years that causes decreased distal muscle strength and poor timing of muscle activation. After completion of medical treatment, ALL childhood cancer survivors (ALL CCS) are more likely to have an inactive lifestyle, resulting in life-long gross motor proficiency differences compared to their peers. ALL CCS typically do not utilize physical therapists' expertise after medical treatment has been completed. There are limited physical therapy (PT) intervention studies for ALL CCS.

Read the detailed description

We are performing a feasibility study to examine a movement based intervention that utilizes fast movements through jumping rope to improve balance, coordination, movement speed, and movement agility. The abilities to generate fast movements are required to perform functional activities and for playing sports. Participants will receive five in-person PT sessions and a home program for six weeks. The goal of this research is to determine the feasibility, acceptability, and promise of a PT program that emphasizes fast movements in ALL CCS.

02

Conditions studied

  • Childhood Cancer

Browse trials for

Keywords

  • physical therapy
  • functional mobility
03

In context

Neoplasms

9,610 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.

This study's enrollment of 10 is below the median of 50 across 7,429 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 696 studies on the registry; 131 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 63 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children 6-17 years old
  • Completed medical treatment for ALL within the past five years (1 to 60 months)
  • Speak English.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a neurological disorder such as cerebral palsy, Down syndrome
  • Currently receiving PT services.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    One group that all receive the intervention of jumping rope.

    All participants will be in one group. Every participant receives the same intervention.

    Behavioral: JUMP

Interventions

  • BehavioralJUMP

    Warm-up, stretching, jumping rope, cool-down

06

What researchers measure

Primary outcomes

  1. Gross Motor Proficiency

    Bruininks-Oseretsky Test of Motor Proficiency 2nd edition (BOT-2) (subtest 4, 5, 6, 8: bilateral coordination, balance, running speed and agility, and strength). The BOT-2 is a reliable and valid norm-referenced instrument designed for children and adolescents 4-21 years old.

    Time frame: 20 minutes

Secondary outcomes

  1. Children's Assessment of Participation and Enjoyment (CAPE) questionnaire.

    The CAPE are designed for use with children ages 6-21 years old.

    Time frame: 10 minutes

  2. electromyography (EMG)

    The EMG onset will be defined by the time when the EMG burst is 3 standard deviations above the baseline muscle activity. The slope of the muscle activity, which is the linear regression line of best fit for the values between the onset of the EMG, and the peak of the EMG burst amplitude will be calculated and normalized by dividing the slope by the peak amplitude. The EMG burst slope reflects the recruitment and firing rate of motor units at the onset of the contraction, which is important for producing fast responses.

    Time frame: 5 minutes

  3. Preferences for Physical Activity for Children (PAC)

    This is a survey to explore physical activity preferences of children.

    Time frame: 10 minutes

  4. Vertical Jump Height

    Participants will perform five vertical jumps starting in the upright standing position with their feet on two adjacent force platforms. The instructions will be to "jump straight up as high as you can".

    Time frame: 5 minutes

  5. Peak vertical ground reaction

    participant is asked to jump on the force platform. Takeoff is defined as the highest vertical ground reaction force value attained from the force time record for the takeoff phase of each jump, minus body mass

    Time frame: 5 minutes

  6. Motion Capture Analysis

    The 3D motion analysis will be captured with a VICON T10 Camera with Nexus Software VICON markers will be placed on each shoe in the position of the great toe, ankle (lateral malleoli), lateral knee (proximal to the apex of the fibular head), greater trochanter of the hip, shoulder (greater tubercle of the humerus), lateral elbow (distal to lateral epicondyle), the wrist (styloid process), and head (wearing a headband).

    Time frame: 5 minutes

07

Study locations

1 site
  • University of Maryland School of Medicine Dept. of Physical Therapy & Rehabilitation Science
    Baltimore, Maryland 21201-1082, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05086354
Responsible party
victoria marchese (Associate Professor, Chair, University of Maryland, Baltimore) — Principal investigator
First posted
Oct 20, 2021
Start date
Mar 16, 2018
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Last update
Feb 11, 2022

Study contacts

Victoria Marchese, PT, PhD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion